Part 4. Thalidomide for Multiple Myeloma (continued)

Excluded Articles

Anaissie E, Miceli ME, Dong L., et al. Safety of total therapy iii for newly diagnosed multiple myeloma: preliminary analysis of 62 consecutive patients.  Blood 2004:104(11), Abstract #935.

Arora R, Mukhopadhyay A, Patel K, et al.   Analysis of safety profile of Thalidomide in Multiple Myeloma: A multicenter Indian experience.  ASCO Annual Meetings 2005;106(11):Abstract #6709.

Badros A, Morris C, Zangari M, et al.   Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leukemia & Lymphoma 2002;43(6):1267-71.

Barlogie B. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Seminars in Hematology 2003;40(4 Suppl 4):33-8.

Barlogie B, Tricot G, Anaissie E, et al. Thalidomide in the management of multiple myeloma.  Seminars in Oncology 2001;28(6):577-82.

Baz R, Marchant K, Yiannaki EO, et al.   Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM).  Blood 2004;104(11):Abstract #2397.

Bertolini F, Mingrone W, Alietti A, et al.   Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Annals of Oncology 2001;12(7):987-90.

Bruno B, Rotta M, Giaccone L, et al.   New drugs for treatment of multiple myeloma. Lancet Oncology 2004;5(7):430-42.

Camba L, Peccatori J, Pescarollo A, et al.   Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001;86(10):1108-9.

Cavo M, Tacchetti P, Zamagni E, et al. Superiority of first-line thalidomide-dexamethasone over vincristine-doxorubicin-dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.  Blood 2004;104(11):Abstract#1489.

Chanan-Khan AA Bcl-2 antisense therapy in multiple myeloma.  Oncology (Huntington) 2004;18(13 Suppl 10):21-24.

Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives.  Journal of Clinical Oncology 2003;21(23):4444-54.

Durie BG. Low-dose thalidomide in myeloma: efficacy and biologic significance.  Seminars in Oncology 2002;29(6 Suppl 17):34-8.

Goldschmidt H, Sonneveld P, Cremer FW, et al.   Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Annals of Hematology 2003;82(10):654-9.

Harousseau JL.. Stem cell transplantation in multiple myeloma (0, 1, or 2). Current Opinion in Oncology 2005;17(2):93-8.

Harousseau JL, Shaughnessy J, Richardson P Multiple myeloma.  Hematology (American Society for Hematology Education Program) 2004;237-56.

Hippe E, Westin J, Wisloff F.  Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care. European Journal of Haematology 2005;74(3):185-93.

Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.  Oncologist 2003:8(Suppl 3):39-45.

Krivanova A, Hajek R, Krejci M, et al. Second autologous transplantation for multiple myeloma patients relapsing after the first autograft―a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group. Onkologie 2004;27(3):275-9.

Morgan AE, Smith WK, Levenson JL. Reversible dementia due to thalidomide therapy for multiple myeloma.  New England Journal of Medicine 2003;348(18):1821-2.

National Horizon Scanning Centre. Thalidomide for multiple myeloma―horizon scanning review. Birmingham, UK: National Horizon Scanning Centre (NHSC):2002.

Owen OG. Trials investigate first-line thalidomide in multiple myeloma.  Lancet Oncology 2005;6(1):6.

Palumbo A, Falco P, Ambrosini MT, et al. Thalidomide and dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Blood 2004;104(11):Abstract #2396.

Pathak RD, Jayaraj K, Blonde L. Thalidomide-associated hyperglycemia and diabetes—case report and review of literature. Diabetes Care 2003;26(4):1322-3.

Pini M, Baraldi A, Pietrasanta D, et al. Low-dose of thalidomide in the treatment of refractory myeloma.  Haematologica 2000;85(10):1111-2.

Pitini V, Arrigo C, Aloi G, et al.   Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.  Bone Marrow Transplantation 2003;31(11):1065.

Richardson P, Anderson KC.  Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.  Journal of Clinical Oncology 2004;22(16):3212-4.

Somlo G. Phase II randomized study of bevacizumab with or without thalidomide in patients with relapsed or refractory multiple myeloma.  National Institutes of Health, Clinical Trials Gov [http://www.clinicaltrials.gov]. 2003.

Thertulien R, Barlogie B, Zangari M, et al. Total Therapy 2 (TT 2) for newly diagnosed patients with multiple myeloma (MM): Examination of dose effect of thalidomide (T) among those randomized to T.  Blood 2004;104(11):Abstract #934.

Urbauer E, Kaufmann H, Nosslinger T, et al.   Thromboembolic events during treatment with thalidomide. Blood 2002;99(11):4247-8.

Zomas A, Anagnostopoulos N, Dimopoulos MA. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplantation 2000;25(12):1319-20.

Return to Contents
Proceed to Next Section